权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Disease-specific risk factors for thrombosis following vascular interventions

血管介入治疗后血栓形成的疾病特异性危险因素

基本信息

批准号：
10733113
负责人：
Vipul C Chitalia
金额：
$ 69.41万
依托单位：
BOSTON MEDICAL CENTER
依托单位国家：
美国
项目类别：
财政年份：
2023
资助国家：
美国
起止时间：
2023-08-01 至 2027-07-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10733113
关键词：
Address Affect American Angioplasty Animal Model Arteries Aryl Hydrocarbon Receptor Biogenesis Biological Markers Blood Blood Vessels Cardiovascular Diseases Carotid Artery Thrombosis Cessation of life Chronic Kidney Failure Clinical Clinical Trials Complication Coronary artery Data Dialysis procedure Disease Enzymes Event Extracellular Matrix Frequencies Gene Silencing Generations Genetic Hemostatic function Human ITIM Indican Inflammation Inflammatory Intervention Investigation Knockout Mice Kynurenine Ligation Mediating Mediator Modeling Molecular Mus Operative Surgical Procedures Organ PDGFRB gene Pathology Pathway interactions Patients Persons Phosphorylation Plasminogen Activator Inhibitor 1 Platelet-Derived Growth Factor beta Receptor Procedures Production Protein-Lysine 6-Oxidase Proteins Regulation Renal function Research Risk Risk Factors Signal Transduction Thromboplastin Thrombosis Time Toxic effect Toxin Tryptophan Tryptophan 2,3 Dioxygenase Tyrosine Up-Regulation Uremia Veins Venous Thrombosis Work burden of illness cost cytokine experience high risk human model inhibitor innovation knockout gene mortality mouse model new therapeutic target novel pharmacologic post intervention solute therapeutic target thrombogenesis thrombotic trend ubiquitin-protein ligase vascular injury

项目摘要

Abstract Vasculo-thrombosis and altered hemostasis are associated with several organ pathologies, the disease- specific mediators of which remain poorly understood. This aspect is particularly relevant in chronic kidney disease (CKD), which affects 30 million Americans. Patients with CKD suffer from high cardiovascular disease burden, making CKD patients in need of frequent vascular interventions, such as endovascular procedures or vascular surgery. A CKD milieu (uremia) is a strong and independent risk factor for thrombosis after such procedures. Given the upward trend of CKD in general, and high frequency of interventional procedures in them, investigating such post-interventional complications and means to control them is a worthy pursuit. CKD is characterized by retention of a host of uremic solutes. Although studies in humans and animal models implicate the uremic solutes indoxyl sulfate and kynurenine as CKD-specific risk factors and are, therefore, perceived as tantalizing therapeutic targets for cardiovascular disease, their exact mechanism of actions remains poorly understood. This underpinning will be addressed in the current proposal. Our work in recent years elucidated prothrombotic propensities of indolic uremic toxins, partially mediating their toxicity through upregulation of tissue factor in vSMCs. Here, building on new data, we propose an integrative approach to study newly identified converging pathways that augment thrombosis in CKD, consisting of Indoleamine 2,3- dioxygenase-1 (IDO1), a key enzyme in kynurenine production, and lysyl oxidase (LOX), a key enzyme regulator of extracellular matrix remodeling and thrombosis. Aim 1 examines a novel regulation of IDO1 level and activity by indoxyl sulfate and/or kynurenine, and its contribution to uremic thrombosis, using genetic and pharmacological manipulation of IDO1 in a CKD mouse model. Aim 2 builds on our new findings suggesting LOX expression as a target of indoxyl sulfate and kynurenine, thereby contributing to uremia-induced vasculo- thrombosis. This aim employs molecular and gene knockout approaches to understand the control of LOX biogenesis in VSMCs in a uremic milieu, and its contribution to thrombosis in context of CKD. Both aims of research will utilize arterial and venous thrombosis models in CKD mice. Successful completion of this proposal will define CKD-associated common mediators of thrombosis. Along with mechanistic advances, our proposed investigations might pave ways to repurposing advanced clinical compounds for the management of vascular occlusion in CKD patients.

摘要